Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 16/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 15/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 11/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8206099 | 0.89 | CTDSP1 (0.47) | CA1CA2PRKAA2MAPK8MAPK9 | |
| SCHEMBL8206615 | 0.89 | PRKAA2 (0.46) | CA1CA2PRKAA2MAPK8MAPK9 | |
| SCHEMBL8205785 | 0.88 | PRKAA2 (0.49) | CA1CA2PRKAA2MAPK8MAPK9 | |
| SCHEMBL12853206 | 0.88 | MAPT (0.54) | PRKAA2MAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL12853219 | 0.87 | PRKAA2 (0.48) | CA1CA2PRKAA2MAPK8MAPK9 | |
| SCHEMBL12853456 | 0.86 | GPR119 (0.51) | — | |
| SCHEMBL8212238 | 0.84 | F10 (0.49) | CA1CA2PRKAA2MAPK8MAPK9 | |
| SCHEMBL8209183 | 0.84 | CA1 (0.51) | CA1CA2PRKAA2MAPK8MAPK9 | |
| SCHEMBL8205747 | 0.83 | MAPT (0.49) | CA1CA2PRKAA2MAPK8MAPK9 | |
| SCHEMBL8211223 | 0.83 | GPR119 (0.50) | CA1CA2PRKAA2MAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2132178-B1 | JNK INHIBITORS | MERCK SHARP & DOHME (US) | 2015-08-19 | — | — | EP | disclosed |
| US-8278337-B2 | Substituted pyridines that are JNK inhibitors | MERCK SHARP & DOHME (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278337-B2 | Substituted pyridines that are JNK inhibitors | MERCK SHARP & DOHME (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100179141-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100179141-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-07-15 | — | — | US | disclosed |
| WO-2008082487-A2 | NOVEL JNK INHIBITORS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179141-A1 | NOVEL JNK INHIBITORS | MAPK1, MAPKAPK5, MAPK15 | CA1 3679/4885CA2 4577/4885PRKAA2 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.